Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma
| Autor: | Debra Fayter, Nasuh Büyükkaramikli, Kate Misso, Frederick W. Thielen, Ching-Yun Wei, Gill Worthy, Isaac Corro Ramos, Rob Riemsma, Nigel Armstrong, Jos Kleijnen, Vanesa Huertas Carrera |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Pediatrics
medicine.medical_specialty Cost effectiveness Follicular lymphoma Nice GROUP PERSPECTIVE 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Maintenance therapy Obinutuzumab Medicine 030212 general & internal medicine health care economics and organizations computer.programming_language Pharmacology business.industry 030503 health policy & services Health Policy Public Health Environmental and Occupational Health medicine.disease Quality-adjusted life year Systematic review chemistry Rituximab 0305 other medical science business computer medicine.drug |
| Zdroj: | Pharmacoeconomics. 37(8):975-984 |
| ISSN: | 1170-7690 |
| DOI: | 10.1007/s40273-018-0740-4 |
| Popis: | The National Institute for Health and Care Excellence (NICE), as part of the institute’s single technology appraisal (STA) process, invited the company that makes obinutuzumab (Roche Products Limited) to submit evidence of the clinical and cost effectiveness of the drug in combination with chemotherapy, with or without obinutuzumab as maintenance therapy for adult patients with untreated, advanced follicular lymphoma (FL) in the UK. Kleijnen Systematic Reviews Ltd (KSR), in collaboration with Erasmus University Rotterdam, was commissioned to act as the Evidence Review Group (ERG). This paper describes the company’s submission, the ERG review, and NICE’s subsequent decisions. The clinical evidence was derived from two phase III, company-sponsored, randomised, open-label studies. Most evidence on obinutuzumab was based on the GALLIUM trial that compared obinutuzumab in combination with chemotherapy as induction followed by obinutuzumab maintenance monotherapy with rituximab in combination with chemotherapy as induction followed by rituximab maintenance monotherapy in previously untreated patients with FL (grades 1–3a). Long-term clinical evidence was based on the PRIMA trial, studying the benefit of two years of rituximab maintenance after first-line treatment in patients with FL. The cost-effectiveness evidence submitted by the company relied on a partitioned survival cost-utility model, implemented in Microsoft® Excel. The base-case incremental cost-effectiveness ratio (ICER) presented in the company submission was |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink